From: A new paradigm evaluating cost per cure of HCV infection in the UK
Patients characteristics | Current study (n = 154) | Stahmeyer et al. (GER) [35] (n = 858)* | Bichoupan et al. (US) [17] (n = 147) |
---|---|---|---|
Age, years [Mean, (SD)] | 49.6 (9.0) | 49.2 (11.2) | 56 (IQR = 51–61) |
Gender, Male [%] | 73.4 | 58 | 68 |
Ethnicity, % | |||
Caucasian [%] | 94.20 % | 97.30 % | Not reported |
Asian [%] | 2.70 % | 0.90 % | Not reported |
African [%] | 1.30 % | 0.80 % | 19 % |
Hispanic [%] | Not reported | 0.50 % | Not reported |
Other [%] | 1.80 % | Not reported | Not reported |
SVR rate by therapy | |||
BOC [%] | 60.8 | 58.1 | Not reported |
TVR [%] | 63.1 | 68.4 | 44 |
Cirrhosis [%] | 21.40 % | Not reported | 36 % |
Prior non-responders [%] | 22.10 % | Not reported | 46 % |
Cost drivers | |||
Drug costs | 94.60 % | 94.6–97.7 % | 89 % |
PIs | 68.30 % | Not reported | Not reported |
TVR | Not reported | Not reported | 61 |
PegIFN | 19.50 % | Not reported | 24 % |
RBV | 6.80 % | Not reported | 4 % |
Outpatient and inpatient care (incl AEs & follow-up) | 5.40 % | 5.4-3.3 % | 8 % |
Cost per SVR ($) | |||
Treatment naïve | 56,576 | 73,473–82,756 | Not reported |
Relapsers | 58,353 | 78,529–93,758 | Not reported |
Non-responders | 125,125 | 127,1049–132,204 | Not reported |
Overall | Not reported | Not reported | 189,000 |